Shri Gopi Chand Group of Institutions

Bāghpat, India

Shri Gopi Chand Group of Institutions

Bāghpat, India
SEARCH FILTERS
Time filter
Source Type

Chanchal C.,Shri Gopi Chand Group of Institutions | Ravi S.,Shri Gopi Chand Group of Institutions | Ankur R.,Shri Gopi Chand Group of Institutions | Harish D.,Maharshi Dayanand University
International Journal of Drug Development and Research | Year: 2012

The liposome drug delivery systems possess significant role in drug formulation in order to improve the therapeutics. The liposomal formulations have been targeted to enhance the therapeutic activity with reduced toxicity. The liposomes can be characterized with respect to physical, chemical and biological parameters. Moreover, the liposomes can be prepared by mechanical method, replacement of organic solvent, fusion of preformed vesicles; and by transformation of size. In addition, liposomes possess various applications which include, treatment of respiratory and eye disorders; brain targeting; cancer therapy; antimicrobial therapy; and gene therapy. The present review discusses about the mechanism, preparation and applications possessed by the liposomes. © 2012 IJDDR, Rohilla Seema et al.


Balakumar P.,Institute of Pharmacy | Rohilla A.,Shri Gopi Chand Group of Institutions | Mahadevan N.,Institute of Pharmacy
Pharmacological Research | Year: 2011

Fenofibrate is a third-generation fibric acid derivative employed clinically as a hypolipidemic agent to lessen the risk caused by atherosclerosis. Dyslipidemia is a condition associated with elevated levels of low-density lipoproteins (LDL), very low-density lipoproteins (VLDL) and triglycerides, and reduced levels of high-density lipoproteins (HDL) in the circulation. Fenofibrate has an ability to diminish LDL, VLDL and triglycerides and pertinently augment HDL, and thus it is used to manage dyslipidemia. The lipid lowering effects of fenofibrate are classically mediated via an activation of peroxisome proliferator-activated receptor-alpha (PPAR-α). Recent studies demonstrated numerous pleiotropic effects of fenofibrate on the heart that afford direct myocardial protection besides its lipid lowering effects. Fenofibrate has an additional potential to prevent the induction and progression of hypertensive heart damage, cardiac hypertrophy, heart failure, myocarditis, lipotoxic cardiomyopathy and vascular endothelial dysfunction-associated cardiovascular abnormalities. In this review, we critically discussed recently identified pleiotropic actions of fenofibrate on the heart. Moreover, the novel cardioprotective effects of fenofibrate against various cardiac disorders have been delineated. © 2010 Elsevier Masson SAS. All rights reserved.


Ankur R.,Shri Gopi Chand Group of Institutions | Arti M.,Shri Gopi Chand Group of Institutions | Ashok K.,Shri Gopi Chand Group of Institutions
International Journal of Drug Development and Research | Year: 2012

Coronary artery disease is the leading causes of morbidity and mortality in man worldwide. Substantial efforts have been dedicated toward improvement of functional recovery and reduction of the extent of infarction after ischemic states. The mitochondrial adenosine triphosphate (ATP)- sensitive potassium channels (mito KATP) is the receptor for KATP channel openers (KCOs) that have been reported to possess protective role against various cardiovascular complications. Several experimental studies have shown a wide range of possible clinical uses of KCOs as bronchodilators, vasodilators and bladder relaxants. In addition, KCOs show various cardioprotective effects against arrhythmias, angina and heart failure. The present article highlights on the physiologic properties and functions of mito KATP channels in the cardiovascular system and on the role of the KCOs in the treatment of various cardiovascular complications. © 2012 IJDDR, Rohilla Ankur et al.


Ankur R.,Shri Gopi Chand Group of Institutions | Pooja D.,Shri Gopi Chand Group of Institutions | Amarjeet D.,Shri Gopi Chand Group of Institutions | Ashok K.,Shri Gopi Chand Group of Institutions
International Journal of Drug Development and Research | Year: 2012

Hyperhomocysteinemia (Hhcy) is a medical condition characterized by abnormally large levels of homocysteine in blood. The involvement of homocysteine (Hcy) in various biochemical reactions causes deficiencies of the vitamins like pyridoxine (B6), folic acid (B9), or B12 leading to higher Hcy levels. Hhcy has been considered as an independent risk factor for various cardiovascular diseases like endothelial dysfunction, vascular inflammation, atherosclerosis, hypertension, cardiac hypertrophy and heart failure. The review article critically explains about the mechanisms involved in the Hhcy-induced development and progression of various cardiovascular disorders. © 2012 IJDDR, Rohilla Ankur et al.


Rohilla A.,Shri Gopi Chand Group of Institutions
Pharmacological Research | Year: 2010

Aminoglycoside antibiotics are employed clinically because of their potent bactericidal activities, less bacterial resistance, post-antibiotic effects and low cost. However, drugs belong to this class are well-known to cause nephrotoxicity, which limits their frequent clinical exploitation. Gentamicin, a commonly used aminoglycoside, is associated with an induction of tubular necrosis, epithelial oedema of proximal tubules, cellular desquamation, tubular fibrosis, glomerular congestion, perivascular edema and inflammation, which ultimately show the way to renal dysfunction. It is a matter of debate whether we have promising agents to prevent the incidence of gentamicin-induced nephrotoxicity. The present review critically discussed the pathogenesis of gentamicin-induced nephrotoxicity. In addition, based on the experimental and clinical studies, the possible therapeutic approach to prevent gentamicin-induced nephrotoxicity has been discussed. © 2010 Elsevier Ltd.


Rohilla A.,Shri Gopi Chand Group of Institutions | Omer N.,Shri Gopi Chand Group of Institutions | Kushnoor A.,Shri Gopi Chand Group of Institutions
International Journal of Pharmacy and Technology | Year: 2012

Diabetic cardiomyopathy (DCM) is a complication of disease associated with coronary artery disease (CAD) and myocardial dysfunction in diabetic patients. Various metabolic perturbations are involved in DCM that include depletion of glucose transporter-4 (GLUT-4), increase of free fatty acids (FFAs), microvascular changes and structural and functional changes in myocardium. A number of signaling mechanisms are involved in the pathogenesis of DCM like metabolic disturbances, myocardial fibrosis, small vessel disease, autonomic dysfunction and insulin resistance. In addition, other molecular factors involved in DCM like reactive oxygen species (ROS), nitric oxide (NO), poly(ADP-ribose) polymerase (PARP), protein kiase C (PKC) and advanced glycation end products (AGEs) have been implicated in the pathogenesis of DCM. This review article seeks to evaluate the evidence for the existence of DCM, clarify the potential signaling mechanisms responsible and possible therapeutic implications for the treatment of DCM.


Rohilla A.,Shri Gopi Chand Group of Institutions | Singh V.,Shri Gopi Chand Group of Institutions | Kushnoor A.,Shri Gopi Chand Group of Institutions
International Journal of Pharmacy and Technology | Year: 2012

Diabetic neuropathy (DN) has been considered as one of the most frequent and troublesome complications of diabetes mellitus. It is the foremost cause of morbidity and mortality among diabetic patients worldwide. In addition, it has been frequently associated with devastating pain. However, the complete knowledge of the history and pathogenesis of the disease remains limited but several mediators have been reported to be involved in the pathogenesis of DN that involve polyol pathway, increased formation of advanced glycation end products (AGEs), enhanced reactive oxygen species (ROS) generation and activation of protein kinase C (PKC). Moreover, management of patients presented with DN has been done by both pharmacological and non-pharmacological strategies. The review critically explains about the pathogenesis and treatment strategies available for the DN.

Loading Shri Gopi Chand Group of Institutions collaborators
Loading Shri Gopi Chand Group of Institutions collaborators